UPDATE: Goldman Sachs Raises PT to $6.60 on Boston Scientific Following Q4 Takeaways

Goldman Sachs maintained Boston Scientific Corporation

with a Sell rating and raised the price target from $5.20 to $6.60. Goldman Sachs noted, "Following 4Q12 results, we adjust our 2013-2016E EPS to reflect: (1) increased sales across most businesses, aside from CRM; (2) revised gross margin assumptions; (3) higher operating expenses; (4) higher interest expense; and (5) increased share repurchases. Still, our revised 2013 sales estimate is now at the low end of guidance (-1.6% vs. the guidance midpoint at -0.7%), as we remain cautious on Boston's business exposure and relative share position." Boston Scientific closed at $7.10 on Tuesday.